Drugs / Tarextumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01277146 | Dec 2010 → Mar 2013 | cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT01647828 | Oct 2012 → Apr 2016 | pancreas disorder | OncoMed Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 1/2 | NCT01859741 | Jan 2012 → Apr 2017 | small cell lung carcinoma | OncoMed Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tarextumab | “Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors.” PMID 31347292 ↗ Jul 20191“A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in” PMID 30591982 ↗ Dec 2018 |
| Known as | OMP-5948 | “Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel...” PMID 30591982 ↗ Dec 2018 |
| Known as | OMP-59R5 | “A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in” PMID 30591982 ↗ Dec 2018 |
| Action | Inhibit | “selectively inhibits signaling via both Notch2 and Notch3” PMID 30591982 ↗ Dec 2018 |
| Modality | Monoclonal antibody | “a novel cross-reactive antibody” PMID 30591982 ↗ Dec 2018 |
| Route | Intravenous | “intravenous (IV) infusions of OMP-59R5” NCT01277146 ↗ |
| Target | NOTCH2 | “binds and selectively inhibits signaling via both Notch2 and Notch3” PMID 30591982 ↗ Dec 2018 |
| Target | NOTCH3 | “binds and selectively inhibits signaling via both Notch2 and Notch3” PMID 30591982 ↗ Dec 2018 |